Marksans Pharma acquires Time-Cap Laboratories

The US-based Time-Cap manufactures solid-dosage generic drugs, including private-label over-the-counter medications, prescription drugs and nutritional supplements


the acquisition increases Marksans' presence in the US market

Mumbai-based drug maker Marksans Pharma has announced that its US subsidiary has bought 100 percent stake in New York-based Time-Cap Laboratories. Financial details of the deal were not disclosed.

According to the company, the acquisition increases its presence in the US market.

"Time-Cap offers Marksans an ideal platform to expand its operation in the US. The strategic acquisition helps Marksans to expand its manufacturing capabilities along with product portfolio and penetration in the US," said Mr Mark Saldanha, managing director and chief executive officer, Marksans Pharma, in a statement.



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email